Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Georgetown University · The Barbara Ann Karmanos Cancer Institute
Abstract
Purpose There are no approved treatments for recurrent/metastatic head and neck squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II KEYNOTE-055 study, we evaluated pembrolizumab, an anti-programmed death 1 receptor antibody, in this platinum- and cetuximab-pretreated population with poor prognosis. Methods Eligibility stipulated disease progression within 6 months of platinum and cetuximab treatment. Patients received pembrolizumab 200 mg every 3 weeks. Imaging was performed every 6 to 9 weeks. Primary end points: overall response rate (Response Evaluation Criteria in Solid Tumors v1.1, central review) and safety. Efficacy was assessed in all dosed patients and in…
Citation impact
- FWCI
- 35.43
- Percentile
- 100%
- References
- 24
Authors
18- JBJoshua BaumlCorresponding
Georgetown University, The Barbara Ann Karmanos Cancer Institute
- TYTanguy Y. Seiwert
Georgetown University, The Barbara Ann Karmanos Cancer Institute
- DGDavid G. Pfister
Georgetown University, The Barbara Ann Karmanos Cancer Institute
- FPFrancis P. Worden
Georgetown University, The Barbara Ann Karmanos Cancer Institute
- SVStephen V. Liu
Georgetown University, The Barbara Ann Karmanos Cancer Institute
Topics & keywords
- Medicine
- Cetuximab
- Pembrolizumab
- Internal medicine
- Adverse effect
- Oncology
- Head and neck cancer
- Refractory (planetary science)
- Good health and well-being